Daré Bioscience, Inc. (NASDAQ:DARE) Sees Significant Decrease in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 35,400 shares, a decline of 9.7% from the August 31st total of 39,200 shares. Based on an average trading volume of 46,900 shares, the short-interest ratio is currently 0.8 days. Currently, 0.4% of the company’s shares are sold short.

Daré Bioscience Price Performance

Daré Bioscience stock traded down $0.04 during mid-day trading on Tuesday, hitting $3.20. 11,974 shares of the company’s stock traded hands, compared to its average volume of 46,074. Daré Bioscience has a fifty-two week low of $3.05 and a fifty-two week high of $7.56. The stock has a market cap of $26.95 million, a price-to-earnings ratio of -0.84 and a beta of 1.39. The firm has a 50 day simple moving average of $3.43 and a two-hundred day simple moving average of $4.27.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.60 million. On average, research analysts anticipate that Daré Bioscience will post -0.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Institutional Trading of Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC increased its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.